GeneExpression Systems, Inc & Appasani Research Conferences and Educational Institute (ARCEI.ORG)
Jointly Presents
Therapeutics Discovery Symposia USA - 2015
Two Theme Meetings at One Location
Genome Engineering & Genome Editing - 2015 Meeting
On
'Synthetic Biology to Zinc Finger Nucleases, TALENs & CRISPRs Regulation'
&
Ubiquitin Biology & Antibody Therapeutics-2015 Meeting
On
‘Proteasomes to Small & Large Molecules for Disease Biology’
Date: MAY 6 – 7, 2015
Venue: Courtyard Marriott, 777 Memorial Drive, Cambridge, MA 02139, USA
Expected Maximum Capacity of each Meeting |
Target Audience |
100 |
Total Speaker Presentations: |
30 |
Total Poster Presentations: |
10 |
Total Exhibit Booths: |
10 |
Click Here For Agenda:TBA
Wednesday, May 6 2015
8:00 AM: Registration Open
9:00 AM - 6:30PM
Scientific Sessions
Thursday, May 7, 2015
8:00 A.M: Registration Open
9:00 AM - 6:30PM
Scientific Sessions
SCOPE OF THE MEETING:
The purpose and scope of this Therapeutics Discovery Symposia USA - 2015 (on May 6 - 7, 2015) is to provide a forum for the discussion of the current state of the art of rapidly evolving Genome Editing, Genome Engineering, Synthetic Biology, Ubiqutin-Proteosome systems and Antibodies as therapeutics which are highly interdisciplinary emerging fields in biotechnology. This will consists of two parallel theme meetings:
1.Genome Engineering & Genome Editing-2015: This is our second international theme conference on Genome Editing. However, part of the theme ‘Genome Engineering’ organized earlier as ‘Frontiers in Synthetic Biology’ meeting since 2008. Nobel Laureate Jack Szostack of the Harvard Medical School inaugurated our first meeting in 2008. Since then, pioneers in synthetic biology including: Drs. Clyde Hutchison III, Wilfried Weber, Pam Silver, Jim Collins, and many more have given keynote speeches. This meeting covers the topic of genome editing mediated by small to long non-coding RNAs, engineering of Nucleases, TALENs and CRISPRs system.
2. Ubiquitin & Antibody Therapeutics-2015: This is our Inaugural international theme conference on the biology of ubiquitin and antibody therapeutics.Currently, both ubiquitin-based drug targets and monoclonal antibody-based drugs are in the mainstream of pharmaceutical industry and they are the block buster drugs in the market place. Several academic, bio-pharmaceutical industry and translational medicine presentations are included in this theme conference from the top-notched institutions and industries in the globe. In this international meeting, prominent researchers (Developmental biologists, cell biologists, geneticists, molecular biologists, structural biologists, computational biologists, neurobiologists, clinicians, chemists and physicists) from both academia and industry will gather and discuss the applications in form of keynote lectures, invited talks, short oral, and poster presentations.
These meetings are open for graduate students, postdoctoral fellows and professors from academia and research scientists and executives from bio-pharma industry to gain insights in the emerging frontiers in biotechnology.
Venue: Courtyard MARRIOTT is a star hotel located on the banks of Charles River in the close vicinity of world renowned Massachusetts Institute of Technology and Harvard University Campuses. This venue is minutes’ walk from the Biotech hub of University Park and Pharmaceutical giants such as: Novartis, Pfizer, Amgen and Takeda.
Note: All the members (except keynote speakers and others who arranged with organizer) who participate in this symposium have to register for the meeting by paying the appropriate registration fee
Scientific Organizer:
|
Krishnarao Appasani, PhD, MBA
Founder & CEO
GeneExpression Systems, Inc
Waltham, MA USA
|
Keynote Speakers:
|
Pamela Silver, PhD.
Elliot T and Onie H. Adams Professor
Wyss Institute &Harvard Medical School
Boston, MA, USA
Title: Programming Biology for Health and Sustainability |
|
Matthew Porteus, MD, PhD.
Associate Professor of Pediatrics
Stanford University Medical School
Stanford, CA, USA
Title: Nuclease-mediated genome engineering and CRISPR-mediated genome editing |
|
HiddeL. Ploegh, PhD.
Professor of Biology& Member
Whitehead Institute-Mass. Inst. of Technology
Cambridge, MA, USA
Title: TBA
Title:Protein quality control and mouse monoclonal antibodies |
|
Alfred Goldberg, PhD.
Professor of Cell Biology
Harvard Medical School
Boston, MA, USA
Title: Ubiquitin proteasome pathway system |
Other Speakers:
Genome Engineering & Genome Editing Speakers: |
Ubiquitin & Antibody Biology-2015 |
|
Erik Sontheimer, PhD.
Professor of Molecular Medicine
University of Massachusetts Medical School
Worcester, MA, USA
Title:CRISPRs and genome editing |
|
Alan D. D'Andrea, MD.
The Fuller-American Cancer Society Professor
Dana-Farber Cancer Inst. &Harvard Medical School
Boston, MA, USA
Title: Targeting Ubiquitin pathways in cancer therapy |
|
Timothy K. Lu, MD., PhD.
Associate Professor of Electrical Engg.
Massachusetts Institute of Technology
Cambridge, MA, USA
Title: Massively parallel combinatorial genetics in bacteria and humans |
|
Michael Strano, PhD.
Professor of Chemical Engineering
Massachusetts Institute of Technology
Cambridge, MA, USA
Title: Synthetic antibodies |
|
J. Chad Brenner, PhD.
Assistant Professor of Surgery
University of Michigan Medical School
Ann Arbor, MI, USA
Title: TBA |
|
Gali Prag, PhD.
Principal Investigatorof Biochemistry s,
Tel Aviv University
Tel Aviv, 69978, Israel
Title: Novel genetic and structural approaches to elucidate the mechanisms for interpretation of the ubiquitin signal |
|
Alfonso Jaramillo, PhD.
Professor of Synthetic Biology
University of Warwick, Coventry, UK &
Instt. of Sys. &Synthetic Biology, Evry, France
Title: TBA |
|
James A. Olzmann, PhD.
Assistant Professorof Toxicology
University of California at Berkeley
Berkeley, CA, USA
Title:Role of ubiquitin in the dynamic adaptation of lipid droplet and autophagy |
|
Wei-Leong Chew,
PhD student in Genetics
Harvard Medical School
Boston, MA, USA
Title:Precise genome engineering in adult mice |
|
Jeffrey D. Parvin, MD, PhD.
Louis Levy Professor for Cancer
The Ohio State University
Columbus, OH, USA
Title: Bookmark ubiquitination of promoter chromatin during mitosis marks active genes in early G1 phase of the cell cycle |
|
Wataru Fujii, PhD.
Assistant ProfessorApplied Genetics
University of Tokyo,
Tokyo, Japan
Title:Efficient generation of genome-modified mice by CRISPR/Cas |
|
Xiaohong (Mary) Zhang, PhD.
Associate Professorof Pathology & Cell Biology
University of South Florida
Tampa, FL, USA
Title:HDAC6 as a deacetylase and E3 ligase |
|
Daniel G. Anderson, PhD.
Samuel A. Goldblith Professor of Chemical Engineering
Massachusetts Institute of Technology
Cambridge, MA, USA
Title:Genome editing with CRISPR/Cas9 system in adult mice corrects genetic diseases |
|
|
|
Dr. Takuya Tsubota
Researcher from the Lab of Dr. Hideki SEZUTSU
National Institute of Agrobiological Sciences
Tsukuba, Ibaraki, Japan
Title:PITCh system - a novel technology for easy and highly efficient gene knock-in |
|
|
|
Benjamin P. Kleinstiver, PhD.
Research Fellow in Pathology
Massachusetts General Hospital
Charlestown, MA, USA
Title: TBA |
|
|
|
Richard L. Frock, PhD.
Fellow in Genetics at Harvard Medical School
Children's Hospital Boston
Boston MA 02115, USA
Title: Double strand break detection with engineered nuclease |
|
|
* Presenting Speaker names, title and times are subject to change.
Host organization, organizer, or scientific committee does not take any kind of responsibility.
Key Topics: |
Genome Engg/Genome Editing-2015 |
Ubiquitin & Antibody Therapeutics -2015 |
- Biology, Design and Delivery Strategies of Nucleases (ZFNs & TALENs)
- Zinc Finger Nucleases & TALENs-based genome editing in model organisms
- Generation of ZFN/TALEN-mediated knockout animals and cell lines
- Epigenetic/Epigenomic editing in stem cells
- RNA-guided genome engineering with CRISPRs
- Engineering Genomes & Organelle using Synthetic Biology
- Gene Engineering & Targeting with Transposons,
- Integrases, Meganucleases & RNA-guided Endonucleases (RGENs)
- Genome Surgery to Engineering using designer nucleases
- High throughput genome editing & Therapeutic applications
|
- Antibody Engineering and Novel Generation Technology
- Small to Large Molecules Drug Discovery
- Antibody-Drug Conjugates
- Immunotherapy and Antibodies as Drugs for Disease Biology
- Ubiquitin Proteasome Systems & Signaling Pathways
- Ubiquitin-Like Proteins and Signalosome-mediated Proteolysis
- UPS in Disease Biology (Allergy, Inflammation, Autophagy,
- Innate Immunity etc).
- UPS/ULPs in Stem cell growth, differentiation, pluripotency & Reprogramming
- UPS/ULPs-based Drug Target Discovery for Therapy & Biomarkers/Diagnostics
|
Exhibitors are welcome to reserve their booth space early!
Please contact if you are interested in speaking in the scientific or Technology workshops of this meeting.
GeneExpression Systems, Inc.
P.O. Box 540170
Waltham, MA 02454 USA
Tel: (781) 891-8181
Fax: (781)730-0700 or (781) 891-8234
E-mail: Genexpsys@expressgenes.com
www.expressgenes.com
Note: Speakers Names, Titles and venue subjected to change beyond our control for which the company is not responsible.
Oral Presentation Submission by March 10, 2015
Poster Abstract Submission by April 20, 2015
Email your abstract (100-200 words in word format) to: genexpsys@expressgenes.com
|